It has been shown that HDAC6 stabilizes EGFR and contributes to TMZ resistance in GBM cells, which is reversed when cells are concurrently treated with the HDAC6 inhibitor CAY10603 [132]. The gene discussed is EGFR; the disease is glioblastoma.